YMAB FY2025 EPS Forecast Decreased by Cantor Fitzgerald

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) – Stock analysts at Cantor Fitzgerald decreased their FY2025 earnings estimates for shares of Y-mAbs Therapeutics in a research report issued to clients and investors on Wednesday, March 5th. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will post earnings of ($0.92) per share for the year, down from their prior estimate of ($0.67). The consensus estimate for Y-mAbs Therapeutics’ current full-year earnings is ($0.65) per share.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The firm had revenue of $26.50 million during the quarter, compared to the consensus estimate of $26.70 million. During the same period in the previous year, the firm earned ($0.02) EPS.

YMAB has been the topic of a number of other research reports. Morgan Stanley dropped their price objective on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a report on Wednesday. Brookline Capital Management assumed coverage on shares of Y-mAbs Therapeutics in a research note on Thursday, December 5th. They set a “buy” rating and a $17.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $22.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday, January 13th. Oppenheimer assumed coverage on Y-mAbs Therapeutics in a research report on Monday, November 18th. They set an “outperform” rating and a $23.00 target price on the stock. Finally, Truist Financial cut their price target on Y-mAbs Therapeutics from $21.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Y-mAbs Therapeutics has an average rating of “Moderate Buy” and an average price target of $19.30.

Y-mAbs Therapeutics Stock Down 1.7 %

Y-mAbs Therapeutics stock opened at $5.16 on Friday. Y-mAbs Therapeutics has a 52-week low of $4.25 and a 52-week high of $18.10. The company has a market cap of $231.11 million, a P/E ratio of -9.56 and a beta of 0.65. The business has a 50-day simple moving average of $6.34 and a two-hundred day simple moving average of $10.54.

Institutional Trading of Y-mAbs Therapeutics

Several institutional investors have recently made changes to their positions in YMAB. State Street Corp lifted its holdings in Y-mAbs Therapeutics by 50.4% in the 3rd quarter. State Street Corp now owns 1,209,781 shares of the company’s stock worth $15,909,000 after purchasing an additional 405,169 shares in the last quarter. Barclays PLC raised its position in shares of Y-mAbs Therapeutics by 433.4% during the third quarter. Barclays PLC now owns 69,222 shares of the company’s stock valued at $910,000 after buying an additional 56,244 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Y-mAbs Therapeutics by 6.2% during the third quarter. Geode Capital Management LLC now owns 813,489 shares of the company’s stock valued at $10,699,000 after buying an additional 47,846 shares during the last quarter. Intech Investment Management LLC purchased a new position in shares of Y-mAbs Therapeutics in the third quarter worth $133,000. Finally, Caligan Partners LP boosted its position in shares of Y-mAbs Therapeutics by 105.3% during the third quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock worth $15,718,000 after acquiring an additional 613,175 shares during the last quarter. Hedge funds and other institutional investors own 70.85% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.